Furthermore, the decrease in IL28A, a type III interferon (102, 103), at the healthiest time point could also contribute to alleviating ME/CFS symptom severity by reducing systemic immune dysregulation, and interferon-associated fatigue, mitigating inflammatory response, and restoring Th1/Th2 balance (104), collectively enhancing cognitive function (105). The gene discussed is IFNL2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.